
PhD Candidate Erasmus School of Health Policy & Management Health Technology Assessment (HTA)
- Location
- Burg. Oudlaan 50, Rotterdam
- Room
- J8-27
- Telephone
- 0104089187
- holleman@eshpm.eur.nl
More information
‹ Back to overview
Profile
- M.S. Holleman, H. van Tinteren, H.J.M. Groen, M.J. Al & C.A. Uyl - de Groot (2019). First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Oncotargets and Therapy, 12, 1413-1421. doi: 10.2147/ott.S189438
- M.S. Holleman, M.J. Al, R. Zaim, H.J.M. Groen & C.A. de Uyl-de Groot (2019). Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. The European Journal Of Health Economics, 21, 153-164. doi: 10.1007/s10198-019-01117-3
- M.S. Holleman, C.A. de Uyl-de Groot, S. Goodall & N. van der Linden (2019). Determining the comparative value of pharmaceutical risk-sharing policies in non-small cell lung cancer using real-world data. Value in Health, 22, 322-331. doi: 10.1016/j.jval.2018.08.007
Master Thesis HEPL
- Title
- Master Thesis HEPL
- Year
- 2020
- Year level
- master
Advanced Health Economic Modelling
- Title
- Advanced Health Economic Modelling
- Year
- 2020
- Year level
- master, master, master
Advanced Health Economic Modelling EuHEM
- Title
- Advanced Health Economic Modelling EuHEM
- Year
- 2020
- Year level
- master
Master Thesis HE
- Title
- Master Thesis HE
- Year
- 2020
- Year level
- master, master
Afstudeerproject
- Title
- Afstudeerproject
- Year
- 2020
- Year level
- bachelor 3
PhD Candidate
- University
- Erasmus University Rotterdam
- School
- Erasmus School of Health Policy & Management
- Department
- Health Technology Assessment (HTA)
- Country
- The Netherlands
- Telephone
- 0104089187